Literature DB >> 17206397

Bone biopsy and densitometry findings in a child with Camurati-Engelmann disease.

Jonas Bondestam1, Mervi K Mäyränpää, Shiro Ikegawa, Eino Marttinen, Heikki Kröger, Outi Mäkitie.   

Abstract

Progressive diaphyseal dysplasia (MIM 131300), also known as Camurati-Engelmann disease (CED), is a rare autosomal dominant craniotubular dysplasia caused by mutations in the transforming growth factor beta1 (TGF-beta1) gene. Radiographs of the long bones of a 9-year-old boy presenting with waddling gait, muscular weakness, underweight, and severe skeletal pain showed symmetric diaphyseal cortical thickening pathognomonic for CED. The diagnosis was verified by detecting a mutation in exon 4 of the TGF-beta1 gene. Full body bone mineral densitometry studies performed before treatment with prednisolone were indicative for osteoporosis (Z-scores for the lumbar spine and femoral neck -2.3 and -3.2, respectively). A transiliac bone biopsy showed markedly reduced trabecular bone volume. Oral prednisolone was initiated, and subsequently, pamidronate infusions were commenced in an attempt to prevent progression of osteoporosis. To our knowledge, this is the first time bone biopsy and bone mineral densitometry studies have been performed and bisphosphonate treatment evaluated in a child with CED.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206397     DOI: 10.1007/s10067-006-0511-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Normative data for iliac bone histomorphometry in growing children.

Authors:  F H Glorieux; R Travers; A Taylor; J R Bowen; F Rauch; M Norman; A M Parfitt
Journal:  Bone       Date:  2000-02       Impact factor: 4.398

2.  Pamidronate in the treatment of progressive diaphyseal dysplasia (Camurati-Engelmann disease)

Authors:  G Chérié-Lignière; G Santalena; A Parafioriti
Journal:  Clin Exp Rheumatol       Date:  1999 Mar-Apr       Impact factor: 4.473

3.  Camurati-Engelmann disease: failure of response to bisphosphonates: report of two cases.

Authors:  Glaucio R W Castro; Simone Appenzeller; João Francisco Marques-Neto; Manoel B Bértolo; Adil M Samara; Ibsen Coimbra
Journal:  Clin Rheumatol       Date:  2005-01-20       Impact factor: 2.980

4.  Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts.

Authors:  R A Ignotz; J Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

5.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

Review 6.  Transforming growth factor-beta1 to the bone.

Authors:  Katrien Janssens; Peter ten Dijke; Sophie Janssens; Wim Van Hul
Journal:  Endocr Rev       Date:  2005-05-18       Impact factor: 19.871

7.  Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.

Authors:  A Kinoshita; T Saito; H Tomita; Y Makita; K Yoshida; M Ghadami; K Yamada; S Kondo; S Ikegawa; G Nishimura; Y Fukushima; T Nakagomi; H Saito; T Sugimoto; M Kamegaya; K Hisa; J C Murray; N Taniguchi; N Niikawa; K Yoshiura
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

8.  Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).

Authors:  T Inaoka; N Shuke; J Sato; Y Ishikawa; K Takahashi; T Aburano; Y Makita
Journal:  Clin Nucl Med       Date:  2001-08       Impact factor: 7.794

9.  A mutation affecting the latency-associated peptide of TGFbeta1 in Camurati-Engelmann disease enhances osteoclast formation in vitro.

Authors:  Neil W A McGowan; Heather MacPherson; Katrien Janssens; Wim Van Hul; Julie C Frith; William D Fraser; Stuart H Ralston; Miep H Helfrich
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

10.  Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females.

Authors:  R R Recker; D B Kimmel; A M Parfitt; K M Davies; N Keshawarz; S Hinders
Journal:  J Bone Miner Res       Date:  1988-04       Impact factor: 6.741

View more
  10 in total

1.  Transforming growth factor-β in stem cells and tissue homeostasis.

Authors:  Xin Xu; Liwei Zheng; Quan Yuan; Gehua Zhen; Janet L Crane; Xuedong Zhou; Xu Cao
Journal:  Bone Res       Date:  2018-01-31       Impact factor: 13.567

2.  Discrepancy between bone density and bone material strength index in three siblings with Camurati-Engelmann disease.

Authors:  S Herrera; R Soriano; X Nogués; R Güerri-Fernandez; D Grinberg; N García-Giralt; N Martínez-Gil; S Castejón; A González-Lizarán; S Balcells; A Diez-Perez
Journal:  Osteoporos Int       Date:  2017-08-25       Impact factor: 4.507

3.  Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.

Authors:  Giampiero I Baroncelli; Elena Ferretti; Cecilia M Pini; Benedetta Toschi; Rita Consolini; Silvano Bertelloni
Journal:  Mol Syndromol       Date:  2017-09-09

Review 4.  Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling.

Authors:  Janet L Crane; Xu Cao
Journal:  J Clin Invest       Date:  2014-02-03       Impact factor: 14.808

Review 5.  Mechanisms of bone pain: Progress in research from bench to bedside.

Authors:  Gehua Zhen; Yuhan Fu; Chi Zhang; Neil C Ford; Xiaojun Wu; Qichao Wu; Dong Yan; Xueming Chen; Xu Cao; Yun Guan
Journal:  Bone Res       Date:  2022-06-06       Impact factor: 13.362

6.  Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand.

Authors:  Michael P Whyte; William G Totty; Deborah V Novack; Xiafang Zhang; Deborah Wenkert; Steven Mumm
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

7.  Transforming Growth Factor β1 (TGF-β1) in the Sera of Postmenopausal Osteoporotic Females.

Authors:  Aazam Faraji; Shabnam Abtahi; Abbas Ghaderi; Alamtaj Samsami Dehaghani
Journal:  Int J Endocrinol Metab       Date:  2016-10-22

8.  Clinical characteristics and treatment outcomes in Camurati-Engelmann disease: A case series.

Authors:  Yoon-Myung Kim; Eungu Kang; Jin-Ho Choi; Gu-Hwan Kim; Han-Wook Yoo; Beom Hee Lee
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

9.  Camurati-Engelmann Disease Complicated by Hypopituitarism: Management Challenges and Literature Review of Outcomes With Bisphosphonates.

Authors:  Liza Das; Vandana Dhiman; Pinaki Dutta; Ashwani Sood; Mahesh Prakash; Simran Kaur; Ellen Steenackers; Gretl Hendrickx; Devi Dayal; Wim Van Hul; Sanjay Kumar Bhadada
Journal:  AACE Clin Case Rep       Date:  2021-10-20

10.  Assessment of bone mineral status in children with Marfan syndrome.

Authors:  Monica Grover; Nicola Brunetti-Pierri; John Belmont; Kelly Phan; Alyssa Tran; Roman J Shypailo; Kenneth J Ellis; Brendan H Lee
Journal:  Am J Med Genet A       Date:  2012-08-07       Impact factor: 2.802

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.